Slides
Page 1
Roy Jakobs, Chief Executive Officer Charlotte Hanneman, Chief Financial Officer November 4, 2025 Third quarter 2025 results
Page 2
© Koninklijke Philips N.V. Table of contents 2 Third quarter 2025 performance 4 2025 outlook 19 Financial appendix 23
Page 3
© Koninklijke Philips N.V. Important information * Non-IFRS financial measure. Refer to reconciliation of non-IFRS information3 Forward-looking statements and other important information This document and the related oral presentation, including responses to questions following the presentation, contain certain forward-looking statements with respect to the financial condition, results of operations and business of Philips and certain of the plans and objectives of Philips with respect to these items. Examples of forward-looking statements include statements made about our strategy, estimates of sales growth, future Adjusted EBITA*, future restructuring and acquisition-related charges and other costs, future developments in Philips’ organic business and the completion of acquisitions and divestments. Forward-looking statements can be identified generally as those containing words such as “anticipates”, “assumes”, “believes”, “estimates”, “expects”, “should”, “will”, “will likely result”, “forecast”, “outlook”, “projects”, “may” or similar expressions. By their nature, these statements involve risk and uncertainty because they relate to future events and circumstances and there are many factors that could cause actual results and developments to differ materially from those expressed or implied by these statements. These factors include, but are not limited to, macro-economic and geopolitical changes – including the war in Ukraine and ongoing tensions in the Middle East – as well as measures such as announced and proposed tariffs and trade actions introduced in response to rising global tensions; Philips’ ability to keep pace with the changing health technology environment; Philips’ ability to gain leadership in health informatics and artificial intelligence in response to developments in the health technology industry; integration of acquisitions and their delivery on business plans and value creation expectations; ability to meet expectations with respect to ESG-related matters; securing and maintaining Philips’ intellectual property rights, and unauthorized use of third-party intellectual property rights; failure of products and services to meet quality or security standards, adversely affecting patient safety and customer operations; the resilience of our supply chain; challenges in simplifying our organization and our ways of working; attracting and retaining personnel; breach of cybersecurity; challenges in driving operational excellence and speed in bringing innovations to market; treasury and financing risks; tax risks; reliability of internal controls; compliance with regulations and standards involving quality, product safety, (cyber) security and artificial intelligence; and compliance with business conduct rules and regulations including privacy, existing and upcoming ESG disclosure and due diligence requirements. As a result, Philips’ actual future results may differ materially from the plans, goals and expectations set forth in such forward-looking statements. For a discussion of factors that could cause future results to differ from such forward-looking statements, see also the Further information chapter included in the Annual Report 2024. Third-party market share data Statements regarding market share contained in this document, including those regarding Philips’ competitive position, are based on outside sources such as specialized research institutes, as well as industry and dealer panels, in combination with management estimates. Where information is not yet available to Philips, market share statements may also be based on estimates and projections prepared by management and/or based on outside sources of information. Management’s estimates of rankings are based on order intake or sales, depending on the business. Market Abuse Regulation This document contains inside information within the meaning of Article 7(1) of the EU Market Abuse Regulation. Use of non-IFRS Information In presenting and discussing the Philips Group’s financial position, operating results and cash flows, management uses certain non-IFRS financial measures. These non-IFRS financial measures should not be viewed in isolation as alternatives to the equivalent IFRS measure and should be used in conjunction with the most directly comparable IFRS measures. Non-IFRS financial measures do not have standardized meaning under IFRS and therefore may not be comparable to similar measures presented by other issuers. A reconciliation of these non-IFRS measures to the most directly comparable IFRS measures is contained in this document. Further information on non-IFRS measures can be found in the Annual Report 2024. Presentation All amounts are in millions of euros unless otherwise stated. Due to rounding, amounts may not add up precisely to totals provided. All reported data is unaudited. Financial reporting is in accordance with the accounting policies as stated in the Annual Report 2024. Certain prior-year balances have been reclassified to conform to the current period presentation. As of September 30, 2025, uncertain tax liabilities were reclassified from non-current tax liabilities to current income tax liabilities. Per share calculations for all periods presented have been retrospectively adjusted to reflect the issuance of shares in 2025 with respect to the share dividend for 2024.
Page 4
© Koninklijke Philips N.V. 4 © Koninklijke Philips N.V. Q3 highlights • Comparable Order Intake up 8%, driven by sustained double-digit growth in North America; order book increased 6% year-on-year • Comparable Sales Growth up 3%, with growth across all three businesses • Adjusted EBITA margin increased 50 bps to 12.3% reflecting higher sales and solid gross margin delivery, driven by innovation, productivity and cost management — more than offsetting tariffs 2025 Outlook • Comparable Sales Growth: reiterated 1% - 3% range • Adjusted EBITA margin: reiterated 11.3% - 11.8% range, expected toward the upper end of the range • Free cash flow: reiterated EUR 0.2 billion-0.4 billion, net of the EUR 1 billion Respironics settlement Key takeaways Numbers updated Red text = old/not updated/not final
Page 5
© Koninklijke Philips N.V. 5 1. Mainly composed of equipment orders in Diagnosis & Treatment and Connected Care businesses Comparable equipment order intake growth1 Indexed equipment order book1 development -2% 8% -4% -2% 0% 2% 4% 6% 8% 10% Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 In the quarter Rolling last twelve months 0% • Order book up 6% year-on-year, with inherent quarterly uneveness; improved gross margin profile driven by recently launched innovations • Order book accounts for ~40% of revenue • Connected Care: strong growth in Monitoring and Informatics • Diagnosis & Treatment: solid growth in Image-Guided Therapy and Ultrasound; decline in Diagnostic Imaging following three consecutive quarters of growth • Sustained double-digit growth in North America Continued order intake growth, combined with robust order book, positions us well to deliver on full-year sales outlook Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025
Page 6
© Koninklijke Philips N.V. Connected Care: Ecosystem platform of choice for patient monitoring, trusted by major hospitals and industry partners 6 10-year partnership with Hoag, Orange County, US • Adopting EMaaS model and latest innovation: IntelliVue MX 750 and X3 monitors and PIC iX platform across Hoag’s network • Creating a seamless monitoring environment that travels with the patient, enhancing both the quality and comfort of care 1. Enterprise Monitoring as a Service Key partnerships signed in Q3 2025 Long-term partnerships with US and European hospitals Rady Children’s Hospital, San Diego adopting EMaaS to enhance efficiency with advanced monitoring, cybersecurity, and scalable digital capabilities US partnership to migrate imaging to the cloud with IntelliSpace Radiology on AWS; PACS services delivered to 50+ institutions in France Renewed Masimo partnership; launched new partnership with Getinge Complementing our longstanding partnerships with Edwards Lifesciences and Medtronic Accelerating the development and delivery of next-generation patient monitoring solutions
Page 7
© Koninklijke Philips N.V. New innovation: Driving long-term momentum in hospitals through sustained innovation investment 7 Rembra RT1 and Areta RT1 Breakthrough in radiation therapy planning, delivering clearer and more consistent images BlueSeal MR RT1 launched in North America Expanding our leadership in sustainable MR for radiation therapy planning Transcend Plus Delivering breakthrough image quality with 26 FDA- cleared cardiovascular AI applications UroNav image-guided navigation system FDA-cleared to enhance precision in minimally invasive prostate cancer therapy Ultrasound Magnetic Resonance Computed Tomography Image-Guided Therapy 1. Radiation therapy
Page 8
© Koninklijke Philips N.V. New innovation: Reinforcing leadership in Personal Health through consumer-winning innovation and retail partnerships 8 1. Based on full year 2024 data. Outside US only | 2. In as few as three treatments; median results on lower legs Lumea IPL launched in North America – exclusively through Amazon U.S. Bringing the world’s No. 1 Intense Pulsed Light hair removal brand1 to the US. Used by over 6 million users and delivers up to 90% hair reduction2 Norelco Head Shaver Pro Series Powered by PowerAdapt Sensor technology, the shaver reads and responds to hair thickness in real time, ensuring a smooth, comfortable shave from start to finish i9000 Prestige Ultra Recognized by TIME as one of the Best Inventions of 2025 Featuring our next-generation SenseIQ Pro AI technology and new Triple Action Lift & Cut system Walmart exclusive Sonicare 6000 and 6400 electric toothbrushes Latest step in Philips Sonicare's mission to improve access to better oral care for millions of Americans
Page 9
© Koninklijke Philips N.V. North America Strong Rest of world Solid Europe Stable Greater China Cautious near term; strong underlying demand 9 Health Systems1 Personal Health Currently stable Strong Subdued Strong Closely monitoring hospital demand and consumer sentiment Key drivers Productivity and consolidation Productivity and digitalization • Impact of anti-corruption act, centralized procurement and stimulus • Regulatory changes and localization Infrastructure investments and digitalization Global hospital demand and consumer sentiment 1. Diagnosis & Treatment and Connected Care businesses
Page 10
© Koninklijke Philips N.V. Diagnosis & Treatment: AI-powered imaging and interventional platforms with intuitive workflows 10 Image-Guided Therapy Azurion 7 High-end platform designed for complex clinical areas such as cardiology, vascular, and neuro interventions EPIQ CVx Premium cardiovascular ultrasound system with powerful AI-based capabilities and advanced diagnostic solutions Ultrasound Magnetic Resonance Computed Tomography CT 5300 80% lower radiation dose and 85% lower image noise Tube for Life guarantee: USD 400K lower operating costs BlueSeal MR 5300 First and only commercially available wide-bore 1.5T helium-free MR
Page 11
© Koninklijke Philips N.V. • 1% sales growth driven by solid Image-Guided Therapy; stable Precision Diagnosis, with strong Ultrasound and modest decline in Diagnostic Imaging due to order timing • Adj. EBITA decreased mainly due to cost inflation and tariffs, partly offset by gross margin from innovations and productivity 11 Diagnosis & Treatment NOTE FROM ZOW: Option A Financial performance In millions of EUR unless otherwise stated Q3 2024 Q3 2025 Sales 2,150 2,080 Comparable sales growth -1% 1% Adj. EBITA margin 12.6% 11.8% Income from operations 232 200 Q3 2025 highlights © Koninklijke Philips N.V.
Page 12
© Koninklijke Philips N.V. Connected Care: Efficient, interoperable monitoring and a real- time data platform spanning different care settings 12 Hospital Patient Monitoring IntelliVue MX monitors Modular, scalable monitoring across the entire patient care journey with unmatched cybersecurity AI-powered PIC iX central monitoring platform Seamlessly connecting data across care settings to streamline workflows and support scalable operations Virtual Patient Avatar Vital signs translated into an avatar using color, shape and animation to help improve clinical decision support Intellivue X3 transport patient monitors Empowering clinicians with accurate, real-time insights for faster, better patient care
Page 13
© Koninklijke Philips N.V. 13 Connected Care © Koninklijke Philips N.V. Q3 2025 highlights Financial performance In millions of EUR unless otherwise stated Q3 2024 Q3 2025 Sales 1,211 1,200 Comparable sales growth 0% 5% Adj. EBITA margin 7.3% 11.4% Income from operations -17 12 • 5% sales growth driven by double-digit growth in Monitoring partly offset by lower Sleep & Respiratory Care sales; stable Enterprise Informatics • Adj. EBITA increased driven by higher sales, favorable mix, and productivity partly offset by cost inflation and tariffs; includes 150 bps gain from minority investment remeasurement
Page 14
© Koninklijke Philips N.V. Personal Health: Innovation-led momentum fueled by premium products, sell-out trends, and marketing investments 14 1. Based on full year 2024 data. Outside the US | 2. In as few as three treatments; median results on lower legs Personal Care Next-gen Diamond Clean Series No.1 dental professional recommended with upgraded plaque removal technology Natural Response Bottles Leading trusted bottle brand, with advanced natural feeding technology that mimics breast function Lumea IPL The world’s No. 1 Intense Pulsed Light hair removal brand1 Lumea delivers up to 90% hair reduction2 Shaver i9000 Intelligent personalization, premium technology Oral Health Care Mother and Child Care OneBlade 360 New hybrid shaving category; 100+ million blades & 50+ million handles sold All in One trimmer One tool, ultimate precision, for face, hair and body
Page 15
© Koninklijke Philips N.V. 15 Personal Health NOTE FROM ZOW: Option A © Koninklijke Philips N.V. Q3 2025 highlights Financial performance In millions of EUR unless otherwise stated Q3 2024 Q3 2025 Sales 835 883 Comparable sales growth -5% 11% Adj. EBITA margin 16.5% 17.1% Income from operations 132 143 • 11% sales growth driven by all three businesses – Grooming & Beauty, Oral Healthcare and Mother & Child Care • Strong growth across most geographies, including North America and growth in China on a low comparison base • Adj. EBITA margin expanded, driven by higher sales and productivity gains, partly offset by higher tariffs and Advertising & Promotion to support demand and product launches
Page 16
© Koninklijke Philips N.V. Delivered a step up in sales growth, margin expansion and solid free cash flow generation 16 4,302 Comparable Sales Growth 3.3% Sales Q3 2025 vs. Q3 2024 In millions of EUR unless otherwise stated 531 Adjusted EBITA margin 12.3%, +50 bps Adjusted EBITA 172 Year-on-year improvement +150 Free Cash Flow • All three business segments grew, partly offset by royalty income phasing • Higher sales, mix improvement and productivity measures, more than offset the impact of increased tariffs and royalty income phasing • Year-on-year improvement reflects higher earnings
Page 17
© Koninklijke Philips N.V. Adjusted EBITA margin driven by sales growth and productivity measures more than offsetting cost inflation and tariffs 17 Group Adj. EBITA margin1 1. Excluding restructuring costs, acquisition-related charges and other items Note: Amounts may not add up due to rounding 11.8% 12.4% 12.3% 12.3%11.8% 0.6% 3.5% -3.6% 0.0% 12.3% Adj. EBITA Q3 2024 Volume and mix Productivity and pricing Cost inflation and tariffs FX, other Adj. EBITA Q3 2025 Incl. impact from royalty income phasing of -0.7% + 50 bps
Page 18
© Koninklijke Philips N.V. Productivity initiatives delivered EUR 566 million year-to-date; on track to deliver EUR 800 million in 2025 18 1. Gross productivity initiatives and re-investments, before inflation EUR 222 million EUR 2,274 million Productivity initiatives savings1 In millions of EUR Q3 2025 To date Q1 2023-Q3 2025 Operating model • Simplified operating model • R&D prioritization, reduction of corporate research projects • End-to-end supply chain, simplifying planning, eliminating duplications 46 894 Procurement • Bill-of-material savings via redesign, value analysis, engineering • Reductions in warehousing, transportation and consulting 47 588 Other productivity • Manufacturing footprint optimization and service productivity • R&D platform simplification and footprint optimization • GBS and hyper-automation • Sleep & Respiratory Care rightsizing 129 792
Page 19
© Koninklijke Philips N.V. 2025 outlook 19
Page 20
© Koninklijke Philips N.V. 2025 Outlook reiterated with Adjusted EBITA margin at upper-end of the range, with currently announced tariffs 20 Comparable sales growth Adjusted EBITA margin Free cash flow1 1%-3% Diagnosis & Treatment and Connected Care growing within the range; Personal Health growing above the range Previous 2025 outlook Updated 2025 outlook 11.3%-11.8% EUR 150-200 million tariff impact net of substantial mitigations Reiterated: 11.3%-11.8% Upper-end of the range EUR 150-200 million tariff impact net of substantial mitigations EUR 0.2 billion-0.4 billion1 Reiterated: EUR 0.2 billion-0.4 billion1 Note: This outlook reflects currently-announced tariff levels; excludes ongoing Philips Respironics-related proceedings, including the investigation by the US Department of Justice 1. After payment EUR 1,025 million cash-out relating to the US medical monitoring and personal injury settlements in Q1 2025 Reiterated: 1%-3% Diagnosis & Treatment slight growth; Connected Care growing within the range Personal Health slightly above the mid-single-digit range
Page 21
© Koninklijke Philips N.V. Restructuring, acquisition-related charges and other items outlook 21 • Mainly related to the Consent Decree, other quality action-related charges, and acquisition-related charges • Further operating model simplification • Manufacturing, R&D footprint, and platform optimization Restructuring costs ~120 bps vs 150 bps last year Otheritems ~180 bps vs 490 bps last year Restructuring costs, other items • EUR 170 million: Diagnosis & Treatment EUR 30 million, Connected Care EUR 115 million, Personal Health EUR 5 million, segment Other EUR 20 million Full-year 2025 Q4 2025 Note: Outlook excludes ongoing Philips Respironics-related proceedings, including the investigation by the US Department of Justice
Page 22
© Koninklijke Philips N.V. Latest FX, below the line items and segment Other outlook 22 Q4 2025 Full year 2025 FX translation1 Diagnosis & Treatment ~(6.0)% ~(3.5)% Connected Care ~(7.0)% ~(4.0)% Personal Health ~(5.0)% ~(3.0)% Philips Group ~(6.0)% ~(3.5)% Effective tax rate 24-26% Financial income and expense (EUR million) ~(240) Segment Other (EUR million) Sales 150-160 550-560 Adj. EBITA ~5 ~flat EBITA ~(15) ~(80) Note: This outlook excludes ongoing Philips Respironics-related proceedings, including the investigation by the US Department of Justice 1. Including consolidation and deconsolidation impact on sales. Based on latest available balance sheet FX rate. Final impact subject to change based on FX movements and geographic sales mix
Page 23
© Koninklijke Philips N.V. Financial appendix 23
Page 24
© Koninklijke Philips N.V. In millions of EUR unless otherwise stated In millions of EUR unless otherwise stated Working capital and inventories 24 Group working capital1 Group inventories Diagnosis & Treatment Connected Care Personal Health as % of LTM sales2 15.5% 11.7% 12.0% 11.9% 12.7% 1,000 1,500 2,000 2,500 3,000 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 14.8% 12.6% 12.7% 12.6% 13.3% 0 500 1,000 1,500 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 19.6% 17.8% 18.6% 18.1% 18.3% 1,500 2,500 3,500 4,500 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 24.2% 16.5% 16.6% 16.0% 17.0% 0 500 1,000 1,500 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 4.8% 2.5% 3.3% 4.4% 5.2% - 150 300 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 as % of LTM sales2 13.4% Excluding insurance receivable* 17.0% * Excluding increase in receivables related to insurance income from Respironics product liability claims 1. Working capital excluding segment Other | 2. As a % of last 12 months sales excluding acquisitions, divestments, and discontinued operations
Page 25
© Koninklijke Philips N.V. 0.0 0.2 0.4 0.6 0.8 1.0 1.2 1.4 1.6 1.8 <12 months 2026 2027 2028 2029 2030 2031 2032 2033 2035 2038 2042 Debt maturity profile and liability management 25 Long-term debt profile and liability management Debt maturity profile as per September 30, 2025 in billions of EUR unless otherwise stated Long-term debt1 Short-term debt2 Un-utilized standby and other committed facilities Forward share repurchases • Total net debt position of EUR 6.5 billion • Maturities up to 2042 • Average tenor of long-term debt is 5.9 years3 • No financial covenants 1. Excluding long-term operating leases | 2. Short-term debt includes local credit facilities that are being rolled forward on a continuous basis as well as Commercial Paper | 3. Based on long-term debt only
Page 26
© Koninklijke Philips N.V. Net capital expenditures, depreciation and amortization 26 In millions of EUR unless otherwise stated Q3 2024 Q3 2025 Net capital expenditures -170 -155 Depreciation -157 -147 Amortization and impairment: -133 -156 of acquired intangible assets -66 -79 of other intangible assets -67 -78 Note: Amounts may not add up due to rounding.
Page 27
© Koninklijke Philips N.V. Restructuring, acquisition-related charges and other items 27 In millions of EUR unless otherwise stated Q1 2024 Q2 2024 Q3 2024 Q4 2024 FY 2024 Q1 2025 Q2 2025 Q3 2025 Restructuring and acquisition- related charges Diagnosis & Treatment 19 25 16 97 157 14 15 6 Connected Care 17 18 19 -1 53 15 17 33 Personal Health - 17 2 5 25 3 5 4 Segment Other 14 41 19 17 92 34 8 13 Philips Group 51 101 56 118 326 67 46 57 Other items Diagnosis & Treatment - 61) - 391) 45 - 211) 221) Connected Care 1,0781)2)3)4) -4891)2)4)5) 502)3)4) 1271)2)4) 765 761)2)4) 201)2)4)6) 361)2)4) Personal Health - - - - - - - - Segment Other 10 1 7 2 20 - - 7 Philips Group 1,088 -483 57 168 830 76 41 65 Restructuring, acquisition- related charges & other items Restructuring 32 83 50 103 268 61 43 52 Acquisition-related charges 19 19 6 15 58 6 3 5 Other items 1,088 -483 57 168 830 76 41 65 Philips Group 1,139 -381 113 286 1,156 143 86 122 1. Quality actions | 2. Respironics running costs | 3. Provision in connection with Respironics litigation | 4. Respironics consent decree charges | 5. Respironics insurance income | 6. Contract settlement gain